London, UK -- (SBWIRE) -- 07/31/2015 -- Anesthesia is a condition in which a patient is loses sensation partially or completely.Anesthetic drugs enable the patient to undergo medical procedures without pain or distress. Anesthetic drugs are broadly segmented into two types, namely, local anesthetic drugs and general anesthetic drugs. Local anesthesia inhibits the sensation to a specific body part, whereas general anesthesia results in loss of sensation and consciousness. General anesthesia provides blockage of pain, awareness and memory.However, combination of these anesthetics is also used for additive or synergistic effects.Administration of general anesthetics provides full control on the body processes, allows complete motionless surgery over prolonged duration.Additionally, it promotes simultaneous performance of the surgeries on different parts of the body.

General Anesthesia Drugs market can be segmented as follows:

By Drugs

Propofol

Sodium pentothal

Ketamine

Fospropofol disodium fentanyl

Others

Browse Full Report@ http://www.futuremarketinsights.com/reports/details/general-anesthesia-drugs-market

Factors such as rapidly increasing geriatric population, rising number of surgeries and growing respiratory, chronic obstructive pulmonary diseases (COPD) and cardiovascular diseases are some of the important factors contributing towards the growth of general anesthesia drugs market globally. Aged population is more prone to cardiovascular diseases and also due to increasing healthcare awareness there is a rise in number of surgeries performed in this population segment. Thus, growing geriatric population will augment the uptake of general anesthesia drugs market globally. According to World Health Organization (WHO) cardiac diseases are expected to become the third leading cause of death globally by 2030. Thus, with the rise in number of people diagnosed with cardiac diseases the demand for general anesthesia drugs will also increase.

Of all the above mentioned commercially available general anesthesia drugs ketamine accounts for the largest share and also is the most preferred drug during medical procedures. Ketamine belongs to theN-methyl D-aspartate (NMDA) receptor class that blocks the effect of neurotransmitter which results in depression of central nervous systems. In North America, Propofol is the most widely used general anesthesia drug owing to fast elimination and rapid onset of action. It is been estimated that the demand for propofol is expected to increase in near future owing to fast patient recovery, fast metabolic clearance and rapid penetration in central nervous system.

Geographically, North America accounted for the largest share of the global general anesthesia drugs market owing rising number of people diagnosed with cardiovascular diseases coupled with growing geriatric population. According to the Center for Disease Control and Prevention (CDC), COPD was the third leading cause of death in the United States in 2011. The American Society of Anestheologists (ASA) estimated a total of40 million anesthetics being administered each year in the country. This rise in respiratory diseases and number of surgeries has boosted the growth of this market. Thus, all the above mentioned factors collectively drive the growth of general anesthesia drugs market in the North American region. Asia-Pacific market is considered to be the most lucrative market owing to rise in number of patient suffering from cardiovascular diseases, rising number of surgeries performed and increasing medical tourism in this region.

Key players involved in the development of generalanesthesia drugs market includes Baxter International Inc., AstraZeneca Plc., Abbott laboratories, BedFord Laboratories, Hospira, Inc., JHP Pharmaceuticals, Eisai Pharmaceuticals and other significant players

The report covers exhaustive analysis on:

Market Segments

Market Dynamics

Historical Actual Market Size, 2012 - 2014

Market Size & Forecast 2015 to 2025

Supply & Demand Value Chain

Current Trends/Issues/Challenges

Competition & Companies involved

Technology

Value Chain

Market Drivers and Restraints

Request Report TOC@ http://www.futuremarketinsights.com/toc/rep-gb-388

Regional analysis includes

North America

US & Canada

Latin America

Brazil, Argentina & Others

Western Europe

EU5

Nordics

Benelux

Eastern Europe

Asia Pacific

Australia and New Zealand (ANZ)

Greater China

India

ASEAN

Rest of Asia Pacific

Japan

Middle East and Africa

GCC Countries

Other Middle East

North Africa

South Africa

Other Africa